Q-omics provides the consensus-scored SOX6 profile across patient tissues and cancer cell-line models. SOX6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SOX6 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SOX6 RNA expression shows 18,599 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where SOX6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOX6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOX6 survival associations across molecular data types. SOX6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOX6 RNA expression–survival associations across cancer types. High SOX6 expression shows unfavorable associations in BLCA, but favorable associations in KIRC, HNSC, MESO, LGG and OV. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SOX6 RNA expression.
This table summarizes SOX6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SOX6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOX6 shows lower tumor expression in KIRC, BRCA, COAD, LUAD, THCA and KICH. The KIRC box plot shows higher SOX6 RNA expression in normal versus tumor tissue (log2 FC = −0.809, t-test p < 0.001).
This table shows molecular features associated with SOX6 in patient tissues and cancer cell lines. In patient samples, SOX6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SOX6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
